Novo Nordisk, the manufacturer of Ozempic, has disclosed a security breach in which hackers infiltrated the company's IT systems, gaining access to personal data1. The pharmaceutical giant's systems were compromised, potentially exposing sensitive information. The breach may have significant implications for the company's operations and supply chain. As a major player in the pharmaceutical industry, Novo Nordisk's security protocols are under scrutiny. The breach may be an indication of evolving attack methods, with hackers targeting high-value targets in the industry. This incident may lead to downstream regulatory effects, as well as potential supply-chain disruptions. So what matters to practitioners is that this breach highlights the need for robust security measures to protect sensitive data and prevent similar incidents in the future.